TASIGNA dosing can work within a daily schedule1
Three options for incorporating TASIGNA into a daily routine1,a
- TASIGNA should be dosed twice daily. Doses should be about 12 hours apart. Each capsule should be swallowed whole with water. Patients must avoid food for 2 hours before and 1 hour after each dose1
- Patients should take 2 TASIGNA capsules in the morning and 2 capsules in the evening1
- If a dose is missed, the patient should not take another dose but rather wait to take the next scheduled dose1
Create an individualized TASIGNA dosing guide for your patient
Use the interactive TASIGNA Daily Dosing Planner to create a personalized TASIGNA dosing guide for your Ph+ CML-CP patients. The application creates a dosing schedule based on a patient’s meal and sleep times. Together you can input the patient’s meal and sleep times, and the application will show the best time to take TASIGNA. The interactive application considers that TASIGNA doses should be about 12 hours apart and patients must avoid food for 2 hours before and 1 hour after each dose.1 You can print the personalized TASIGNA Daily Dosing Planner for your patient.
A Clear dosing regimen that patients can incorporate into their everyday lives1
Choosing the correct dosage of TASIGNA for your patients is simple. TASIGNA capsules come in 2 strengths, in daily dosing packs to help patients adhere to therapy.1
|For newly diagnosed patients1||For imatinib-resistant or -intolerant patients1|
|Prescribe 300 mg (2 x 150-mg capsules) twice daily||Prescribe 400 mg (2 x 200-mg capsules) twice daily|
TASIGNA must not be taken with food1
- Patients should not eat for at least 2 hours before and at least 1 hour after taking TASIGNA
- If a dose is missed, patients should not make up the dose, but take the next dose as scheduled.
- For patients who are unable to swallow capsules, the contents of each capsule may be dispersed in 1 teaspoon of applesauce (puréed apple) and should be taken immediately. Not more than 1 teaspoon of applesauce and no food other than applesauce may be used.
TASIGNA should NOT be taken at any time with grapefruit juice1
Other foods that are known to inhibit CYP3A4 should be avoided while taking TASIGNA.
TASIGNA may need to be temporarily withheld and/or dose reduced for toxicities that are not related to underlying leukemia. Please see the full prescribing information for guidance on TASIGNA dose reductions and adjustments.
Remind your patients—TASIGNA can interact with certain foods and drugs
It is important that your patients keep you informed about all of the medications and over-the-counter supplements that they are taking. Remind them that they need to let you and any other doctors they visit know that they are taking TASIGNA before new medications are prescribed.
TASIGNA may interact with antiarrhythmics, inducers and inhibitors of CYP3A4, and CYP3A4 substrates including, but not limited to, the following1:
|Antiarrhythmics—used to treat irregular heartbeat||Midazolam—used to relieve anxiety before surgery|
|Chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin—medicines that may have an unwanted effect on the function of the heart||Alfentanil and fentanyl – used to treat pain and as a sedative before or during surgery or medical procedures|
|Ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin—used to treat infections||Cyclosporine, sirolimus and tacrolimus – medicines that suppress the “self-defense” ability of the body and fight infections and are commonly used to prevent the rejection of transplanted organs such as the liver, heart and kidney|
|Ritonavir—a medicine from the class “antiproteases,” used to treat HIV||Dihydroergotamine and ergotamine – used to treat dementia|
|Carbamazepine, phenobarbital, phenytoin—used to treat epilepsy||Lovastatin, simvastatin – used to treat high level of fats in blood|
|Rifampicin—used to treat tuberculosis||Warfarin—used to treat blood coagulation disorders (such as blood clots or thrombosis)|
|St John’s wort—an herbal product used to treat depression and other conditions (also known as Hypericum perforatum)||Astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, or ergot alkaloids (ergotamine, dihydroergotamine)|
- TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; May 2017.